CaaMTech Secures $22 Million Series A Led by Noetic Fund to Push Psychedelic Drug Candidates into Human Trials
CaaMTech raised $22 million in a Series A led by Noetic Fund to advance its analytically pure psychedelic compound library toward human clinical trials, expand its leadership team, and support its cross-disciplinary research program.
More: GeekWire
-
GeekWire / Charlotte Schubert: Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing